Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

30.03.15	Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload (GlobeNewswire)
30.03.15	Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group (GlobeNewswire)
21.03.15	Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients (GlobeNewswire)
20.03.15	New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients (GlobeNewswire)
17.03.15	Novartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer (GlobeNewswire)
17.03.15	Novartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer (GlobeNewswire)
13.03.15	Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skin (GlobeNewswire)
13.03.15	Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skin (GlobeNewswire)
06.03.15	FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz (GlobeNewswire)
02.03.15	Novartis gibt Abschluss von Transaktionen mit GSK bekannt (GlobeNewswire)
02.03.15	Novartis announces completion of transactions with GSK (GlobeNewswire)
27.02.15	Positive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular degeneration (GlobeNewswire)
27.02.15	Novartis shareholders approve all resolutions proposed by Novartis Board of Directors (GlobeNewswire)
27.02.15	Aktionäre genehmigen alle Anträge des Verwaltungsrats von Novartis (GlobeNewswire)
27.02.15	Novartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinib (GlobeNewswire)
23.02.15	Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma (GlobeNewswire)
13.02.15	Novartis' heart failure medicine LCZ696 granted FDA priority review (GlobeNewswire)
02.02.15	Alcon receives FDA approval of Pazeo(TM) Solution for ocular allergy itch relief (GlobeNewswire)
28.01.15	Novartis announces study in NEJM showing Jakavi® was superior to standard therapy in rare blood cancer polycythemia vera (GlobeNewswire)
27.01.15	Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses (GlobeNewswire)
23.01.15	Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, the leading cause of bacterial meningitis in the US (GlobeNewswire)
23.01.15	Novartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera (GlobeNewswire)
21.01.15	Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients (GlobeNewswire)
19.01.15	Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients (GlobeNewswire)
08.01.15	Novartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA (GlobeNewswire)
07.01.15	Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee (GlobeNewswire)
07.01.15	Novartis collaborates with Intellia Therapeutics and Caribou Biosciences to explore making medicines and drug discovery tools with CRISPR genome editing technology (GlobeNewswire)
01.01.15	Novartis completes divestment of Animal Health business to Eli Lilly for USD 5.4 billion (GlobeNewswire)
26.12.14	First in the world regulatory approval of Novartis' Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis (GlobeNewswire)
23.12.14	Alcon treatment Travatan® receives EU approval for pediatric glaucoma patients (GlobeNewswire)
16.12.14	Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder (GlobeNewswire)
12.12.14	Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS (GlobeNewswire)
12.12.14	Head-to-head psoriasis study demonstrates superiority of Novartis Cosentyx(TM) to Stelara® in clearing skin (GlobeNewswire)
08.12.14	Novartis announces safety and efficacy benefit of Jakavi® in global clinical trial of over 1,000 patients with myelofibrosis (GlobeNewswire)
08.12.14	Six-year pivotal study data reinforce the superiority of Tasigna® over Glivec® in newly-diagnosed patients with Ph+ CML (GlobeNewswire)
08.12.14	Phase III data shows Sandoz' investigational biosimilar filgrastim has similar safety and efficacy as Amgen's NEUPOGEN® (GlobeNewswire)
06.12.14	Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia (GlobeNewswire)
02.12.14	Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014 (GlobeNewswire)
01.12.14	Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS) (GlobeNewswire)
28.11.14	Novartis' heart failure medicine LCZ696 granted accelerated assessment by CHMP in Europe[1] (GlobeNewswire)
25.11.14	Novartis announces extension to FDA review period for multiple myeloma investigational compound LBH589 (GlobeNewswire)
24.11.14	Novartis drug Signifor® approved in EU, marking an advance for patients with inadequately controlled acromegaly (GlobeNewswire)
21.11.14	Novartis Foundation symposium showcases sustainable healthcare interventions (GlobeNewswire)
21.11.14	Novartis Stiftung präsentiert an ihrem Symposium nachhaltige Gesundheitsinterventionen (GlobeNewswire)
21.11.14	Novartis Cosentyx(TM) receives positive CHMP opinion for first-line treatment of moderate-to-severe psoriasis patients (GlobeNewswire)
17.11.14	Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients[1],[2] (GlobeNewswire)
16.11.14	Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients (GlobeNewswire)
15.11.14	Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients (GlobeNewswire)
12.11.14	Novartis und Malaria No More helfen Sambia das Behandlungsziel für Malaria zu erreichen, indem sie durch Power of One drei Millionen Behandlungseinheiten finanzieren (GlobeNewswire)
12.11.14	Novartis and Malaria No More help fulfill malaria treatment goal in Zambia by raising funds for three million treatments through Power of One (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

23.05.25		Roche-Aktie steigt: Neuigkeiten zu Augenmedikament Susvimo und Krebsmittel Columvi - Kooperation in den USA
23.05.25		Bayer-Aktie etwas stärker: Empfehlung für 6-monatige Anwendung von Eylea 8mg - USA überraschend mild gegenüber Pestiziden
23.05.25		DAX 40-Wert Bayer-Aktie: So viel Verlust hätte eine Investition in Bayer von vor 5 Jahren bedeutet
23.05.25		SMI-Titel Roche-Aktie: So viel Verlust hätte ein Roche-Investment von vor 3 Jahren eingebracht
22.05.25		Sanofi-Aktie tiefer: Sanofi stärkt Neurologie-Portfolio mit Übernahme von Vigil Neuroscience
22.05.25		Bayer-Aktie gefragt: Bayer sichert sich China-Zulassung für neue Eylea-Dosierung
21.05.25		Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel hätten Anleger mit einem Investment in Johnson Johnson von vor 5 Jahren verdient

23.05.25

Roche-Aktie steigt: Neuigkeiten zu Augenmedikament Susvimo und Krebsmittel Columvi - Kooperation in den USA

23.05.25

Bayer-Aktie etwas stärker: Empfehlung für 6-monatige Anwendung von Eylea 8mg - USA überraschend mild gegenüber Pestiziden

23.05.25

DAX 40-Wert Bayer-Aktie: So viel Verlust hätte eine Investition in Bayer von vor 5 Jahren bedeutet

23.05.25

SMI-Titel Roche-Aktie: So viel Verlust hätte ein Roche-Investment von vor 3 Jahren eingebracht

22.05.25

Sanofi-Aktie tiefer: Sanofi stärkt Neurologie-Portfolio mit Übernahme von Vigil Neuroscience

22.05.25

Bayer-Aktie gefragt: Bayer sichert sich China-Zulassung für neue Eylea-Dosierung

21.05.25

Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel hätten Anleger mit einem Investment in Johnson Johnson von vor 5 Jahren verdient

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’097.00	0.71 %	K V
Nestle	88.52	0.42 %	K V
Roche Hldg G	259.90	0.27 %	K V
Swisscom	568.50	0.00 %	K V
Lonza Grp	560.00	-0.11 %	K V
UBS Group	26.09	-1.84 %	K V
Sonova Hldg	263.50	-1.90 %	K V
CieFinRichemont	156.65	-2.28 %	K V
Logitech Intl	69.14	-3.57 %	K V
Part Grp Hldg	1’071.00	-5.22 %	K V

Novartis Aktie VALOR 1200526 / ISIN CH0012005267

Nachrichten zu Novartis AG

Aktien Top/Flop

Novartis Peer Group Nachrichten

Meistgelesene Nachrichten